Header Logo

Connection

Douglas Golenbock to Lipopolysaccharides

This is a "connection" page, showing publications Douglas Golenbock has written about Lipopolysaccharides.
Connection Strength

6.461
  1. Meng J, Gong M, Bj?rkbacka H, Golenbock DT. Genome-wide expression profiling and mutagenesis studies reveal that lipopolysaccharide responsiveness appears to be absolutely dependent on TLR4 and MD-2 expression and is dependent upon intermolecular ionic interactions. J Immunol. 2011 Oct 01; 187(7):3683-93.
    View in: PubMed
    Score: 0.300
  2. Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol. 2005 Nov 15; 175(10):6465-72.
    View in: PubMed
    Score: 0.201
  3. Henneke P, Morath S, Uematsu S, Weichert S, Pfitzenmaier M, Takeuchi O, M?ller A, Poyart C, Akira S, Berner R, Teti G, Geyer A, Hartung T, Trieu-Cuot P, Kasper DL, Golenbock DT. Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J Immunol. 2005 May 15; 174(10):6449-55.
    View in: PubMed
    Score: 0.194
  4. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, Golenbock DT. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med. 2003 Oct 06; 198(7):1043-55.
    View in: PubMed
    Score: 0.174
  5. Visintin A, Latz E, Monks BG, Espevik T, Golenbock DT. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem. 2003 Nov 28; 278(48):48313-20.
    View in: PubMed
    Score: 0.173
  6. Espevik T, Latz E, Lien E, Monks B, Golenbock DT. Cell distributions and functions of Toll-like receptor 4 studied by fluorescent gene constructs. Scand J Infect Dis. 2003; 35(9):660-4.
    View in: PubMed
    Score: 0.165
  7. Latz E, Visintin A, Lien E, Fitzgerald KA, Espevik T, Golenbock DT. The LPS receptor generates inflammatory signals from the cell surface. J Endotoxin Res. 2003; 9(6):375-80.
    View in: PubMed
    Score: 0.165
  8. Fierer J, Swancutt MA, Heumann D, Golenbock D. The role of lipopolysaccharide binding protein in resistance to Salmonella infections in mice. J Immunol. 2002 Jun 15; 168(12):6396-403.
    View in: PubMed
    Score: 0.159
  9. Ingalls RR, Lien E, Golenbock DT. Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through toll-like receptor 2. Infect Immun. 2001 Apr; 69(4):2230-6.
    View in: PubMed
    Score: 0.146
  10. Lien E, Chow JC, Hawkins LD, McGuinness PD, Miyake K, Espevik T, Gusovsky F, Golenbock DT. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway. J Biol Chem. 2001 Jan 19; 276(3):1873-80.
    View in: PubMed
    Score: 0.142
  11. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest. 2000 Feb; 105(4):497-504.
    View in: PubMed
    Score: 0.135
  12. Ingalls RR, Lien E, Golenbock DT. Differential roles of TLR2 and TLR4 in the host response to Gram-negative bacteria: lessons from a lipopolysaccharide-deficient mutant of Neisseria meningitidis. J Endotoxin Res. 2000; 6(5):411-5.
    View in: PubMed
    Score: 0.134
  13. Heine H, Delude RL, Monks BG, Espevik T, Golenbock DT. Bacterial lipopolysaccharide induces expression of the stress response genes hop and H411. J Biol Chem. 1999 Jul 23; 274(30):21049-55.
    View in: PubMed
    Score: 0.130
  14. Heine H, Kirschning CJ, Lien E, Monks BG, Rothe M, Golenbock DT. Cutting edge: cells that carry A null allele for toll-like receptor 2 are capable of responding to endotoxin. J Immunol. 1999 Jun 15; 162(12):6971-5.
    View in: PubMed
    Score: 0.129
  15. Ingalls RR, Heine H, Lien E, Yoshimura A, Golenbock D. Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Infect Dis Clin North Am. 1999 Jun; 13(2):341-53, vii.
    View in: PubMed
    Score: 0.129
  16. Ingalls RR, Monks BG, Golenbock DT. Membrane expression of soluble endotoxin-binding proteins permits lipopolysaccharide signaling in Chinese hamster ovary fibroblasts independently of CD14. J Biol Chem. 1999 May 14; 274(20):13993-8.
    View in: PubMed
    Score: 0.128
  17. Dowling JK, Tate MD, Rosli S, Bourke NM, Bitto N, Lauterbach MA, Cheung S, Ve T, Kobe B, Golenbock D, Mansell A. The Single Nucleotide Polymorphism Mal-D96N Mice Provide New Insights into Functionality of Mal in TLR Immune Responses. J Immunol. 2019 04 15; 202(8):2384-2396.
    View in: PubMed
    Score: 0.126
  18. Delude RL, Yoshimura A, Ingalls RR, Golenbock DT. Construction of a lipopolysaccharide reporter cell line and its use in identifying mutants defective in endotoxin, but not TNF-alpha, signal transduction. J Immunol. 1998 Sep 15; 161(6):3001-9.
    View in: PubMed
    Score: 0.123
  19. Ingalls RR, Arnaout MA, Delude RL, Flaherty S, Savedra R, Golenbock DT. The CD11/CD18 integrins: characterization of three novel LPS signaling receptors. Prog Clin Biol Res. 1998; 397:107-17.
    View in: PubMed
    Score: 0.117
  20. Wurfel MM, Monks BG, Ingalls RR, Dedrick RL, Delude R, Zhou D, Lamping N, Schumann RR, Thieringer R, Fenton MJ, Wright SD, Golenbock D. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med. 1997 Dec 15; 186(12):2051-6.
    View in: PubMed
    Score: 0.116
  21. Ingalls RR, Arnaout MA, Golenbock DT. Outside-in signaling by lipopolysaccharide through a tailless integrin. J Immunol. 1997 Jul 01; 159(1):433-8.
    View in: PubMed
    Score: 0.113
  22. Qureshi N, Kaltashov I, Walker K, Doroshenko V, Cotter RJ, Takayama K, Sievert TR, Rice PA, Lin JS, Golenbock DT. Structure of the monophosphoryl lipid A moiety obtained from the lipopolysaccharide of Chlamydia trachomatis. J Biol Chem. 1997 Apr 18; 272(16):10594-600.
    View in: PubMed
    Score: 0.111
  23. Savedra R, Delude RL, Ingalls RR, Fenton MJ, Golenbock DT. Mycobacterial lipoarabinomannan recognition requires a receptor that shares components of the endotoxin signaling system. J Immunol. 1996 Sep 15; 157(6):2549-54.
    View in: PubMed
    Score: 0.107
  24. Levitz SM, Tabuni A, Nong SH, Golenbock DT. Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide. Infect Immun. 1996 Mar; 64(3):945-51.
    View in: PubMed
    Score: 0.103
  25. Ingalls RR, Rice PA, Qureshi N, Takayama K, Lin JS, Golenbock DT. The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun. 1995 Aug; 63(8):3125-30.
    View in: PubMed
    Score: 0.099
  26. Golenbock DT, Bach RR, Lichenstein H, Juan TS, Tadavarthy A, Moldow CF. Soluble CD14 promotes LPS activation of CD14-deficient PNH monocytes and endothelial cells. J Lab Clin Med. 1995 May; 125(5):662-71.
    View in: PubMed
    Score: 0.097
  27. Ingalls RR, Golenbock DT. CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med. 1995 Apr 01; 181(4):1473-9.
    View in: PubMed
    Score: 0.096
  28. Delude RL, Savedra R, Yamamoto S, Golenbock DT. Use of CD14 transfected cells to study LPS-antagonist action. Prog Clin Biol Res. 1995; 392:487-97.
    View in: PubMed
    Score: 0.095
  29. Fagan MA, Liu Y, St?tz P, Vyplel H, Golenbock DT. Acyclic analogue of lipid A stimulates TNF-alpha and arachidonate release via a unique LPS-signaling pathway. J Immunol. 1994 Dec 01; 153(11):5230-8.
    View in: PubMed
    Score: 0.094
  30. Delude RL, Fenton MJ, Savedra R, Perera PY, Vogel SN, Thieringer R, Golenbock DT. CD14-mediated translocation of nuclear factor-kappa B induced by lipopolysaccharide does not require tyrosine kinase activity. J Biol Chem. 1994 Sep 02; 269(35):22253-60.
    View in: PubMed
    Score: 0.093
  31. Golenbock DT, Liu Y, Millham FH, Freeman MW, Zoeller RA. Surface expression of human CD14 in Chinese hamster ovary fibroblasts imparts macrophage-like responsiveness to bacterial endotoxin. J Biol Chem. 1993 Oct 15; 268(29):22055-9.
    View in: PubMed
    Score: 0.087
  32. Lynn WA, Liu Y, Golenbock DT. Neither CD14 nor serum is absolutely necessary for activation of mononuclear phagocytes by bacterial lipopolysaccharide. Infect Immun. 1993 Oct; 61(10):4452-61.
    View in: PubMed
    Score: 0.087
  33. Lynn WA, Golenbock DT. Lipopolysaccharide antagonists. Immunol Today. 1992 Jul; 13(7):271-6.
    View in: PubMed
    Score: 0.080
  34. Lynn WA, Raetz CR, Qureshi N, Golenbock DT. Lipopolysaccharide-induced stimulation of CD11b/CD18 expression on neutrophils. Evidence of specific receptor-based response and inhibition by lipid A-based antagonists. J Immunol. 1991 Nov 01; 147(9):3072-9.
    View in: PubMed
    Score: 0.076
  35. Meng J, Lien E, Golenbock DT. MD-2-mediated ionic interactions between lipid A and TLR4 are essential for receptor activation. J Biol Chem. 2010 Mar 19; 285(12):8695-702.
    View in: PubMed
    Score: 0.067
  36. Nagpal K, Plantinga TS, Wong J, Monks BG, Gay NJ, Netea MG, Fitzgerald KA, Golenbock DT. A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling. J Biol Chem. 2009 Sep 18; 284(38):25742-8.
    View in: PubMed
    Score: 0.064
  37. Diczfalusy U, Olofsson KE, Carlsson AM, Gong M, Golenbock DT, Rooyackers O, Fl?ring U, Bj?rkbacka H. Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J Lipid Res. 2009 Nov; 50(11):2258-64.
    View in: PubMed
    Score: 0.064
  38. Knapp S, von Aulock S, Leendertse M, Haslinger I, Draing C, Golenbock DT, van der Poll T. Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol. 2008 Mar 01; 180(5):3478-84.
    View in: PubMed
    Score: 0.059
  39. Visintin A, Iliev DB, Monks BG, Halmen KA, Golenbock DT. MD-2. Immunobiology. 2006; 211(6-8):437-47.
    View in: PubMed
    Score: 0.053
  40. Rowe DC, McGettrick AF, Latz E, Monks BG, Gay NJ, Yamamoto M, Akira S, O'Neill LA, Fitzgerald KA, Golenbock DT. The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc Natl Acad Sci U S A. 2006 Apr 18; 103(16):6299-304.
    View in: PubMed
    Score: 0.052
  41. Cario E, Golenbock DT, Visintin A, R?nzi M, Gerken G, Podolsky DK. Trypsin-sensitive modulation of intestinal epithelial MD-2 as mechanism of lipopolysaccharide tolerance. J Immunol. 2006 Apr 01; 176(7):4258-66.
    View in: PubMed
    Score: 0.052
  42. Knapp S, Florquin S, Golenbock DT, van der Poll T. Pulmonary lipopolysaccharide (LPS)-binding protein inhibits the LPS-induced lung inflammation in vivo. J Immunol. 2006 Mar 01; 176(5):3189-95.
    View in: PubMed
    Score: 0.051
  43. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem. 2005 Apr 29; 280(17):17005-12.
    View in: PubMed
    Score: 0.048
  44. Fitzgerald KA, Rowe DC, Golenbock DT. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect. 2004 Dec; 6(15):1361-7.
    View in: PubMed
    Score: 0.047
  45. Wieland CW, Knapp S, Florquin S, de Vos AF, Takeda K, Akira S, Golenbock DT, Verbon A, van der Poll T. Non-mannose-capped lipoarabinomannan induces lung inflammation via toll-like receptor 2. Am J Respir Crit Care Med. 2004 Dec 15; 170(12):1367-74.
    View in: PubMed
    Score: 0.047
  46. Bj?rkbacka H, Fitzgerald KA, Huet F, Li X, Gregory JA, Lee MA, Ordija CM, Dowley NE, Golenbock DT, Freeman MW. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics. 2004 Nov 17; 19(3):319-30.
    View in: PubMed
    Score: 0.046
  47. Kaneko T, Goldman WE, Mellroth P, Steiner H, Fukase K, Kusumoto S, Harley W, Fox A, Golenbock D, Silverman N. Monomeric and polymeric gram-negative peptidoglycan but not purified LPS stimulate the Drosophila IMD pathway. Immunity. 2004 May; 20(5):637-49.
    View in: PubMed
    Score: 0.045
  48. Lien E, Golenbock DT. Adjuvants and their signaling pathways: beyond TLRs. Nat Immunol. 2003 Dec; 4(12):1162-4.
    View in: PubMed
    Score: 0.044
  49. Medvedev AE, Lentschat A, Wahl LM, Golenbock DT, Vogel SN. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol. 2002 Nov 01; 169(9):5209-16.
    View in: PubMed
    Score: 0.041
  50. Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, Golenbock DT, Espevik T. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem. 2002 Dec 06; 277(49):47834-43.
    View in: PubMed
    Score: 0.040
  51. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci. 2002 Jun 15; 115(Pt 12):2603-11.
    View in: PubMed
    Score: 0.040
  52. Henneke P, Golenbock DT. Innate immune recognition of lipopolysaccharide by endothelial cells. Crit Care Med. 2002 May; 30(5 Suppl):S207-13.
    View in: PubMed
    Score: 0.039
  53. Ellingsen E, Morath S, Flo T, Schromm A, Hartung T, Thiemermann C, Espevik T, Golenbock D, Foster D, Solberg R, Aasen A, Wang J. Induction of cytokine production in human T cells and monocytes by highly purified lipoteichoic acid: involvement of Toll-like receptors and CD14. Med Sci Monit. 2002 May; 8(5):BR149-56.
    View in: PubMed
    Score: 0.039
  54. Yoshimura A, Kaneko T, Kato Y, Golenbock DT, Hara Y. Lipopolysaccharides from periodontopathic bacteria Porphyromonas gingivalis and Capnocytophaga ochracea are antagonists for human toll-like receptor 4. Infect Immun. 2002 Jan; 70(1):218-25.
    View in: PubMed
    Score: 0.039
  55. Medvedev AE, Henneke P, Schromm A, Lien E, Ingalls R, Fenton MJ, Golenbock DT, Vogel SN. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J Immunol. 2001 Aug 15; 167(4):2257-67.
    View in: PubMed
    Score: 0.037
  56. Schromm AB, Lien E, Henneke P, Chow JC, Yoshimura A, Heine H, Latz E, Monks BG, Schwartz DA, Miyake K, Golenbock DT. Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med. 2001 Jul 02; 194(1):79-88.
    View in: PubMed
    Score: 0.037
  57. Golenbock DT, Fenton MJ. Extolling the diversity of bacterial endotoxins. Nat Immunol. 2001 Apr; 2(4):286-8.
    View in: PubMed
    Score: 0.037
  58. Flo TH, Ryan L, Kilaas L, Skj?k-Braek G, Ingalls RR, Sundan A, Golenbock DT, Espevik T. Involvement of CD14 and beta2-integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers. Infect Immun. 2000 Dec; 68(12):6770-6.
    View in: PubMed
    Score: 0.036
  59. Moore KJ, Andersson LP, Ingalls RR, Monks BG, Li R, Arnaout MA, Golenbock DT, Freeman MW. Divergent response to LPS and bacteria in CD14-deficient murine macrophages. J Immunol. 2000 Oct 15; 165(8):4272-80.
    View in: PubMed
    Score: 0.035
  60. Pereira LMN, Assis PA, de Ara?jo NM, Durso DF, Junqueira C, Ata?de MA, Pereira DB, Lien E, Fitzgerald KA, Zamboni DS, Golenbock DT, Gazzinelli RT. Caspase-8 mediates inflammation and disease in rodent malaria. Nat Commun. 2020 09 14; 11(1):4596.
    View in: PubMed
    Score: 0.035
  61. Means TK, Golenbock DT, Fenton MJ. The biology of Toll-like receptors. Cytokine Growth Factor Rev. 2000 Sep; 11(3):219-32.
    View in: PubMed
    Score: 0.035
  62. Flo TH, Halaas O, Lien E, Ryan L, Teti G, Golenbock DT, Sundan A, Espevik T. Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol. 2000 Feb 15; 164(4):2064-9.
    View in: PubMed
    Score: 0.034
  63. Means TK, Lien E, Yoshimura A, Wang S, Golenbock DT, Fenton MJ. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol. 1999 Dec 15; 163(12):6748-55.
    View in: PubMed
    Score: 0.033
  64. Tejera D, Mercan D, Sanchez-Caro JM, Hanan M, Greenberg D, Soreq H, Latz E, Golenbock D, Heneka MT. Systemic inflammation impairs microglial A? clearance through NLRP3 inflammasome. EMBO J. 2019 09 02; 38(17):e101064.
    View in: PubMed
    Score: 0.033
  65. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol. 1999 Jul 01; 163(1):1-5.
    View in: PubMed
    Score: 0.032
  66. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999 Apr 16; 274(16):10689-92.
    View in: PubMed
    Score: 0.032
  67. Skjesol A, Yurchenko M, B?sl K, Gravastrand C, Nilsen KE, Gr?vdal LM, Agliano F, Patane F, Lentini G, Kim H, Teti G, Kumar Sharma A, Kandasamy RK, Sporsheim B, Starheim KK, Golenbock DT, Stenmark H, McCaffrey M, Espevik T, Husebye H. The TLR4 adaptor TRAM controls the phagocytosis of Gram-negative bacteria by interacting with the Rab11-family interacting protein 2. PLoS Pathog. 2019 03; 15(3):e1007684.
    View in: PubMed
    Score: 0.032
  68. Solomon KR, Kurt-Jones EA, Saladino RA, Stack AM, Dunn IF, Ferretti M, Golenbock D, Fleisher GR, Finberg RW. Heterotrimeric G proteins physically associated with the lipopolysaccharide receptor CD14 modulate both in vivo and in vitro responses to lipopolysaccharide. J Clin Invest. 1998 Dec 01; 102(11):2019-27.
    View in: PubMed
    Score: 0.031
  69. Ingalls RR, Monks BG, Savedra R, Christ WJ, Delude RL, Medvedev AE, Espevik T, Golenbock DT. CD11/CD18 and CD14 share a common lipid A signaling pathway. J Immunol. 1998 Nov 15; 161(10):5413-20.
    View in: PubMed
    Score: 0.031
  70. Bliss CM, Golenbock DT, Keates S, Linevsky JK, Kelly CP. Helicobacter pylori lipopolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial neutrophil-activating peptide 78, and monocyte chemotactic protein 1 by human monocytes. Infect Immun. 1998 Nov; 66(11):5357-63.
    View in: PubMed
    Score: 0.031
  71. Fenton MJ, Golenbock DT. LPS-binding proteins and receptors. J Leukoc Biol. 1998 Jul; 64(1):25-32.
    View in: PubMed
    Score: 0.030
  72. Medvedev AE, Flo T, Ingalls RR, Golenbock DT, Teti G, Vogel SN, Espevik T. Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappaB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J Immunol. 1998 May 01; 160(9):4535-42.
    View in: PubMed
    Score: 0.030
  73. Pollack M, Ohl CA, Golenbock DT, Di Padova F, Wahl LM, Koles NL, Guelde G, Monks BG. Dual effects of LPS antibodies on cellular uptake of LPS and LPS-induced proinflammatory functions. J Immunol. 1997 Oct 01; 159(7):3519-30.
    View in: PubMed
    Score: 0.029
  74. Lodie TA, Savedra R, Golenbock DT, Van Beveren CP, Maki RA, Fenton MJ. Stimulation of macrophages by lipopolysaccharide alters the phosphorylation state, conformation, and function of PU.1 via activation of casein kinase II. J Immunol. 1997 Feb 15; 158(4):1848-56.
    View in: PubMed
    Score: 0.027
  75. Yang H, Wang H, Ju Z, Ragab AA, Lundb?ck P, Long W, Valdes-Ferrer SI, He M, Pribis JP, Li J, Lu B, Gero D, Szabo C, Antoine DJ, Harris HE, Golenbock DT, Meng J, Roth J, Chavan SS, Andersson U, Billiar TR, Tracey KJ, Al-Abed Y. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med. 2015 Jan 12; 212(1):5-14.
    View in: PubMed
    Score: 0.024
  76. Janssen E, Ozcan E, Liadaki K, Jabara HH, Manis J, Ullas S, Akira S, Fitzgerald KA, Golenbock DT, Geha RS. TRIF signaling is essential for TLR4-driven IgE class switching. J Immunol. 2014 Mar 15; 192(6):2651-8.
    View in: PubMed
    Score: 0.022
  77. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem. 1991 Oct 15; 266(29):19490-8.
    View in: PubMed
    Score: 0.019
  78. Franklin BS, Ishizaka ST, Lamphier M, Gusovsky F, Hansen H, Rose J, Zheng W, Ata?de MA, de Oliveira RB, Golenbock DT, Gazzinelli RT. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3689-94.
    View in: PubMed
    Score: 0.018
  79. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA, Lambe EM, Creagh EM, Golenbock DT, Tschopp J, Kornfeld H, Fitzgerald KA, Lavelle EC. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem. 2011 Mar 18; 286(11):9587-97.
    View in: PubMed
    Score: 0.018
  80. Golenbock DT, Hampton RY, Raetz CR, Wright SD. Human phagocytes have multiple lipid A-binding sites. Infect Immun. 1990 Dec; 58(12):4069-75.
    View in: PubMed
    Score: 0.018
  81. Birkland TP, Cornwell RD, Golenbock DT, Proctor RA. Comparative study of lipopolysaccharide-, lipid IVa-, and lipid X-induced tumor necrosis factor production in murine macrophage-like cell lines. Adv Exp Med Biol. 1990; 256:399-402.
    View in: PubMed
    Score: 0.017
  82. Cornwell RD, Golenbock DT, Proctor RA. Lipopolysaccharide, but not lethal infection, releases tumor necrosis factor in mice. Adv Exp Med Biol. 1990; 256:585-8.
    View in: PubMed
    Score: 0.017
  83. Palsson-McDermott EM, Doyle SL, McGettrick AF, Hardy M, Husebye H, Banahan K, Gong M, Golenbock D, Espevik T, O'Neill LA. TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway. Nat Immunol. 2009 Jun; 10(6):579-86.
    View in: PubMed
    Score: 0.016
  84. Henneke P, Dramsi S, Mancuso G, Chraibi K, Pellegrini E, Theilacker C, H?bner J, Santos-Sierra S, Teti G, Golenbock DT, Poyart C, Trieu-Cuot P. Lipoproteins are critical TLR2 activating toxins in group B streptococcal sepsis. J Immunol. 2008 May 01; 180(9):6149-58.
    View in: PubMed
    Score: 0.015
  85. Nordone SK, Ignacio GA, Su L, Sempowski GD, Golenbock DT, Li L, Dean GA. Failure of TLR4-driven NF-kappa B activation to stimulate virus replication in models of HIV type 1 activation. AIDS Res Hum Retroviruses. 2007 Nov; 23(11):1387-95.
    View in: PubMed
    Score: 0.014
  86. Taylor KR, Yamasaki K, Radek KA, Nardo AD, Goodarzi H, Golenbock D, Beutler B, Gallo RL. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem. 2007 Jun 22; 282(25):18265-18275.
    View in: PubMed
    Score: 0.014
  87. Visintin A, Halmen KA, Khan N, Monks BG, Golenbock DT, Lien E. MD-2 expression is not required for cell surface targeting of Toll-like receptor 4 (TLR4). J Leukoc Biol. 2006 Dec; 80(6):1584-92.
    View in: PubMed
    Score: 0.013
  88. McGettrick AF, Brint EK, Palsson-McDermott EM, Rowe DC, Golenbock DT, Gay NJ, Fitzgerald KA, O'Neill LA. Trif-related adapter molecule is phosphorylated by PKC{epsilon} during Toll-like receptor 4 signaling. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9196-201.
    View in: PubMed
    Score: 0.013
  89. Santos-Sierra S, Golenbock DT, Henneke P. Toll-like receptor-dependent discrimination of streptococci. J Endotoxin Res. 2006; 12(5):307-12.
    View in: PubMed
    Score: 0.013
  90. Mann PB, Wolfe D, Latz E, Golenbock D, Preston A, Harvill ET. Comparative toll-like receptor 4-mediated innate host defense to Bordetella infection. Infect Immun. 2005 Dec; 73(12):8144-52.
    View in: PubMed
    Score: 0.013
  91. Romics L, Dolganiuc A, Velayudham A, Kodys K, Mandrekar P, Golenbock D, Kurt-Jones E, Szabo G. Toll-like receptor 2 mediates inflammatory cytokine induction but not sensitization for liver injury by Propioni- bacterium acnes. J Leukoc Biol. 2005 Dec; 78(6):1255-64.
    View in: PubMed
    Score: 0.012
  92. Srivastava A, Henneke P, Visintin A, Morse SC, Martin V, Watkins C, Paton JC, Wessels MR, Golenbock DT, Malley R. The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease. Infect Immun. 2005 Oct; 73(10):6479-87.
    View in: PubMed
    Score: 0.012
  93. Yang X, Coriolan D, Murthy V, Schultz K, Golenbock DT, Beasley D. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am J Physiol Heart Circ Physiol. 2005 Sep; 289(3):H1069-76.
    View in: PubMed
    Score: 0.012
  94. Johnson AC, Heinzel FP, Diaconu E, Sun Y, Hise AG, Golenbock D, Lass JH, Pearlman E. Activation of toll-like receptor (TLR)2, TLR4, and TLR9 in the mammalian cornea induces MyD88-dependent corneal inflammation. Invest Ophthalmol Vis Sci. 2005 Feb; 46(2):589-95.
    View in: PubMed
    Score: 0.012
  95. Zamboni DS, Campos MA, Torrecilhas AC, Kiss K, Samuel JE, Golenbock DT, Lauw FN, Roy CR, Almeida IC, Gazzinelli RT. Stimulation of toll-like receptor 2 by Coxiella burnetii is required for macrophage production of pro-inflammatory cytokines and resistance to infection. J Biol Chem. 2004 Dec 24; 279(52):54405-15.
    View in: PubMed
    Score: 0.012
  96. Branger J, Florquin S, Knapp S, Leemans JC, Pater JM, Speelman P, Golenbock DT, van der Poll T. LPS-binding protein-deficient mice have an impaired defense against Gram-negative but not Gram-positive pneumonia. Int Immunol. 2004 Nov; 16(11):1605-11.
    View in: PubMed
    Score: 0.012
  97. Finberg RW, Re F, Popova L, Golenbock DT, Kurt-Jones EA. Cell activation by Toll-like receptors: role of LBP and CD14. J Endotoxin Res. 2004; 10(6):413-8.
    View in: PubMed
    Score: 0.011
  98. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem. 2002 Oct 18; 277(42):39320-6.
    View in: PubMed
    Score: 0.010
  99. Means TK, Jones BW, Schromm AB, Shurtleff BA, Smith JA, Keane J, Golenbock DT, Vogel SN, Fenton MJ. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol. 2001 Mar 15; 166(6):4074-82.
    View in: PubMed
    Score: 0.009
  100. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol. 1999 Oct 01; 163(7):3920-7.
    View in: PubMed
    Score: 0.008
  101. Bhat N, Perera PY, Carboni JM, Blanco J, Golenbock DT, Mayadas TN, Vogel SN. Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression. J Immunol. 1999 Jun 15; 162(12):7335-42.
    View in: PubMed
    Score: 0.008
  102. Flaherty SF, Golenbock DT, Milham FH, Ingalls RR. CD11/CD18 leukocyte integrins: new signaling receptors for bacterial endotoxin. J Surg Res. 1997 Nov; 73(1):85-9.
    View in: PubMed
    Score: 0.007
  103. Ryan LK, Golenbock DT, Wu J, Vermeulen MW. Characterization of proinflammatory cytokine production and CD14 expression by murine alveolar macrophage cell lines. In Vitro Cell Dev Biol Anim. 1997 Sep; 33(8):647-53.
    View in: PubMed
    Score: 0.007
  104. Stern A, Engelhardt R, Foster C, Golenbock D, Hildebrandt J, Landmann R, Mayer P, St?tz P. SDZ MRL 953, a lipid A analog as selective cytokine inducer. Prog Clin Biol Res. 1995; 392:549-65.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.